MNPR vs ITG Comparison

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

ITG Inc provides services to the digital and other utility infrastructure industries throughout the United States. Its services support the planning, design, construction, operation, maintenance, and expansion of broadband and other infrastructure networks. It operates through two complementary service lines: i) Engineering & Maintenance: It provides re-occurring, mission-critical services required by network owners to operate, maintain, optimize and expand their infrastructure. ii) Infrastructure Deployment. It provides large-scale network and fiber construction services for incumbent carriers, overbuilders, and data center operators and underground civil construction services for public and private utilities. The majority of revenue is derived from the Engineering & Maintenance services.